HOPE FOR A CURE....
BEGINS WITH RESEARCH

The research program was developed in 1995 to explore additional treatment options for patients of the practice. In March 2015, we joined the National Community Oncology Research Program (NCORP), essentially establishing a small satellite of the National Cancer Institute (NCI) in Arroyo Grande. This increases access to new NCI-sponsored clinical trials for local patients. Because of efficiencies in the NCORP, overhead for the research program decreased, permitting us to use more of our resources for research and patient services.

In addition to the trials listed we have access to about 75 clinical trials reviewed by the NCI CIRB.  If you are interested in a clinical trial that is not listed ask Ruth Mares (Ruth@PCROncology.com) if we have access to it.

 

Open Clinical Trials as of May 2026

 

BREAST CANCER

  • S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer.

BASKET TRIALS

  • ULI-EAP-100: Expanded access to ulixertinib (BVD-523) in patients with advanced MAPK pathway-altered malignancies

  • A212102: Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detecting

  • URCC-18007: Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

  • DCP-001: Use of a Clinical Trial Screening Tool to Address Barriers to Clinical Trial Accrual in the NCI Community Oncology Research Program (NCORP)

  • WF2304-A172401: Complementary Options for Symptom Management in Cancer (COSMIC):Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (NCT#06418204)

LUNG

  • LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  • A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

MYELOMA

  • EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

 

For more information please contact:
Ruth Mares at Ruth@pcroncology.com or call (805) 474-9143